Journal
LEUKEMIA
Volume 19, Issue 1, Pages 34-38Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2403566
Keywords
tumor lysis; hyperuricemia; uric acid; urate oxidase; Rasburicase; Elitek (TM)
Categories
Funding
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
- NCI NIH HHS [CA 21765] Funding Source: Medline
Ask authors/readers for more resources
The recombinant urate oxidase, rasburicase (Elitekt(TM), Sanofi-Synthelabo, Inc.), has recently received regulatory approval for the prevention and treatment of hyperuricemia in children with leukemia, lymphoma, and solid tumors. Prior to approval, 682 children and 387 adults in the US and Canada received rasburicase on compassionate-use basis. Uric acid concentration declined rapidly in both adult and pediatric patients after rasburicase treatment. Similar responses were observed in patients treated with subsequent courses. Possible drug-related adverse events, including allergic reactions, were uncommon. These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available